SynthesisInternational urogynecology journal2021
A systematic review of neurocognitive dysfunction with overactive bladder medications.
Synthesis in International urogynecology journal, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 52 citations in OpenAlex.
- A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin.Acta neuropathologica · 2024Trial
- Peroneal electrical transcutaneous neuromodulation (peroneal eTNMWorld journal of urology · 2026Review
- Recent Technological Advances in Monitoring and Neuromodulation of Non-Malignant and Neurogenic Bladder Conditions.Advanced healthcare materials · 2026Review
- Review
- Review
- The Impact of Real-world Use of Overactive Bladder Medications on Dementia Risk in Younger Adults.European urology open science · 2025Article
- Utility of unique optical properties of Anethum graveolens green synthesized mediated-alumina nanoparticles for spectrofluorometric determination of darifenacin in pharmaceutical products.Scientific reports · 2025Article
- Clinical and urodynamic benefit of adding antimuscarinics after a loss of efficacy of intradetrusor botulinum toxin in patients with multiple sclerosis.World journal of urology · 2025Article
- Article
- In Silico Electrophysiological Investigation of Transient Receptor Potential Melastatin-4 Ion Channel Biophysics to Study Detrusor Overactivity.International journal of molecular sciences · 2024Article
- Evaluation and management of urinary incontinence in nursing home residents: unique considerations for an at-risk population.Gynecology and pelvic medicine · 2024Review
- [Polypharmacy in patients with dementia].Innere Medizin (Heidelberg, Germany) · 2024Review
- Menopausal Hormone Therapy in Older Women: Examining the Current Balance of Evidence.Drugs & aging · 2023Review
- Penny-wise but Pound-foolish: The Hidden Costs of Step Therapy for Overactive Bladder.The Journal of urology · 2023Article
- Overactive bladder medication - do we need to revisit trospium chloride for our elderly patients?International urogynecology journal · 2023Article
- Sex differences in urological management during spinal cord injury rehabilitation: results from a prospective multicenter longitudinal cohort study.Spinal cord · 2023Article
- The Impact of Anticholinergic Use for Overactive Bladder on Cognitive Changes in Adults with Normal Cognition, Mild Cognitive Impairment, or Dementia.European urology open science · 2022Article
- A Clinical Review on Paroxetine and Emerging Therapies for the Treatment of Vasomotor Symptoms.International journal of women's health · 2022Review
- Overactive Bladder Symptoms Within Nervous System: A Focus on Etiology.Frontiers in physiology · 2021Review
- Antimuscarinics for neurogenic overactive bladder in multiple sclerosis: real-life data.Therapeutic advances in urologyArticle
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
5 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introduction and hypothesisThe aim of this study is to report cognitive dysfunction with commonly used antimuscarinic overactive bladder medications in patients suffering from overactive bladder disorder with and without baseline neurologic conditions.
methodsWe conducted an Ovid MEDLINE, Embase, and PsycINFO search from January 1998 to December 2018 using PRISMA guidelines. Eighteen studies met the inclusion criteria, including 5 randomized controlled trials and 13 observational studies.
resultsCognitive decline was reported with oxybutynin use (5 of 8 studies) and tolterodine use (4 of 7 studies) among patients with and without baseline cognitive impairment. Oxybutynin use was linked to functional, mental, and behavioral decline among patients with Alzheimer's disease (2 studies). No cognitive decline was detected among patients with and without baseline cognitive impairment taking trospium (6 studies), darifenacin (3 studies), imidafenacin (2 studies), and fesoterodine (1 study). Solifenacin was not associated with cognitive decline (2 studies) but was linked to an increased risk of dementia among patients with diabetes (1 study).
conclusionIn this review, cognitive decline was reported with oxybutynin and tolterodine use and should be used with caution in adults over 65 years of age. Solifenacin, fesoterodine, and imidafenacin showed mixed results related to central nervous system effect. Trospium and darifenacin were not associated with cognitive decline among patients with and without baseline cognitive impairment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.